NCT06343090View on ClinicalTrials.gov

Clinical Trial of CD19 and CD22 CAR Sequential Therapy Versus Single CD19 CAR Bridging to HSCT for r/r B-ALL Patients

NARecruitingINTERVENTIONAL
Enrollment

353

Participants

Timeline

Start Date

April 12, 2024

Primary Completion Date

December 1, 2042

Study Completion Date

September 30, 2043

Conditions
B-cell Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia, in RelapseRefractory Acute Lymphoid Leukemia
Interventions
DRUG

CD19 CAR T-cell

Murine-derived CD19 CAR T cells

DRUG

CD22 CAR T cells

humanized CD22 CAR T cells

PROCEDURE

hematopoietic stem-cell transplantation

allo-HSCT

Trial Locations (1)

102206

RECRUITING

Beijing GoBroad Hospital, Beijing

All Listed Sponsors
collaborator

The General Hospital of Western Theater Command

OTHER

collaborator

Zhaxin Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai

OTHER

collaborator

Shanghai Liquan Hospital

OTHER

lead

Beijing GoBroad Hospital

OTHER